Ceapro Reports Third Quarter 2013 Financial Results

Ceapro Reports Third Quarter 2013 Financial Results

ID: 315998

(firmenpresse) - EDMONTON, ALBERTA -- (Marketwired) -- 11/13/13 -- November 13, 2013 - Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today released its financial results for the three-month and nine-month periods ended September 30, 2013.

FINANCIAL RESULTS FOR THE THIRD QUARTER AND THE FIRST NINE MONTHS ENDED SEPTEMBER 30, 2013

"We are very pleased with our 2013 year to date results showing an increase of revenues of $1,059,000 or 26.7% compared to the first nine months of 2012 and showing a net profit of $280,000 compared to a net loss of $301,000 for the same period in 2012" said Gilles Gagnon, President and CEO. " This result, which includes the two highest quarterly revenues in Ceapro's history, is even more impressive considering they were achieved during a year where we are building a new facility which requires significant investment and resources" he added.

The complete financial statements are available for review on SEDAR at and on the Company's website at .

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CEAPRO INC.

Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

Unaudited





Contacts:
Branko Jankovic
Vice President and CFO
Ceapro Inc.
T (Edmonton): 780.917.8376
E:



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  LifeSci Advisors Initiates Coverage of NeoStem, Inc. COTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent Protection
Bereitgestellt von Benutzer: Marketwired
Datum: 13.11.2013 - 14:00 Uhr
Sprache: Deutsch
News-ID 315998
Anzahl Zeichen: 0

contact information:
Town:

EDMONTON, ALBERTA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 177 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ceapro Reports Third Quarter 2013 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Ceapro Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ceapro Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z